Private Equity in Cancer Care
Over the past two decades, private equity has quietly embedded itself into the backbone of America’s cancer care system. What was once a largely physician-led field has been rapidly consolidated into investor-controlled networks that span oncology clinics, imaging centers, specialty pharmacies, and billing operations.
Drawn by high demand and Medicare reimbursement rules that reward expensive drugs and procedures, private equity firms have acquired hundreds of oncology practices nationwide, reshaping how cancer care is delivered and financed. This transformation is not merely structural—it has fundamentally altered the incentives that guide treatment decisions.
That shift has come at a measurable cost to patients. Studies cited in the report show that private equity–owned oncology practices raise prices more than any other medical specialty while delivering worse outcomes. Patients treated at these facilities face higher complication and mortality rates for certain cancer procedures, while physicians are pushed to see more patients in less time and rely more heavily on high-cost therapies.
As financial pressure intensifies, clinical judgment is increasingly subordinated to revenue targets, eroding physician independence and narrowing treatment options, particularly in low-income and rural communities.
The risks extend beyond higher bills and poorer care. The report documents a long trail of fraud, kickbacks, data breaches, and bankruptcies tied to private equity–backed cancer providers, leaving patients abruptly displaced and communities without essential services.
Regulators and state lawmakers are now responding with renewed antitrust enforcement and efforts to curb corporate control of medicine, even as industry-backed groups aggressively lobby to preserve the status quo.
Without stronger oversight, the financialization of cancer care threatens not just affordability, but the integrity and stability of a system patients rely on at their most vulnerable moments.
